Compare FSUN & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSUN | URGN |
|---|---|---|
| Founded | 1892 | 2004 |
| Country | United States | United States |
| Employees | N/A | 253 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 966.0M | 1.1B |
| IPO Year | N/A | 2017 |
| Metric | FSUN | URGN |
|---|---|---|
| Price | $38.36 | $23.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $46.33 | $28.50 |
| AVG Volume (30 Days) | 138.6K | ★ 773.4K |
| Earning Date | 01-26-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.52 | N/A |
| EPS | ★ 3.16 | N/A |
| Revenue | ★ $384,497,000.00 | $96,516,000.00 |
| Revenue This Year | $19.09 | $27.96 |
| Revenue Next Year | $62.50 | $123.20 |
| P/E Ratio | $12.14 | ★ N/A |
| Revenue Growth | ★ 10.48 | 8.00 |
| 52 Week Low | $29.95 | $3.42 |
| 52 Week High | $45.32 | $30.00 |
| Indicator | FSUN | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.72 | 48.71 |
| Support Level | $37.13 | $22.60 |
| Resistance Level | $40.07 | $24.14 |
| Average True Range (ATR) | 1.06 | 1.17 |
| MACD | 0.10 | -0.09 |
| Stochastic Oscillator | 64.32 | 49.09 |
Firstsun Capital Bancorp is the financial holding company. It provides a full range of deposit, lending, treasury management, wealth management, and online banking products and services. The company operates in two segments - Banking operations and mortgage operations, the majority of which are generated by the banking operations segment. The Banking segment originates loans and provides deposits and fee based services to consumer, business, and mortgage lending customers. Products offered include a full range of commercial and consumer banking and financial services. The Mortgage Operations segment originates, sells, services, and manages market risk from changes in interest rates on one-to-four family residential mortgage loans.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.